3Shape's strategic adjustment in Greater China; Shining 3D plans to raise 550 million yuan through a

3Shape's Greater China strategy and business model have been adjusted to maintain local production and server operations.

On December 4, 2025, 3Shape, a Danish digital dental company, announced that it would adjust its business model and organizational structure in Greater China starting this month.

The core of this adjustment lies in a shift in the strategic focus of the business model. Going forward, the focus will be on business collaboration with partners, while continuing to maintain local production, maintenance, and technical support. Servers deployed locally will also continue to be upgraded and optimized to ensure stable operation for users.

According to 3Shape's 2024 annual report, as of December 2024, the company had 152 employees in China. In fiscal year 2024, 3Shape's global revenue was 3.317 billion Danish kroner (approximately 3.658 billion RMB), representing a year-on-year increase of 1.0%.

Recently, Shining 3D Technology Co., Ltd. issued an announcement stating that it plans to publicly issue no more than 23 million shares (including over-allotment option) to unspecified qualified investors and list them on the Beijing Stock Exchange, with a planned fundraising of 550 million yuan for three R&D projects.

Of these, the high-precision digital implant technology research and development project for dentistry is expected to use 160 million yuan of the raised funds, accounting for 29% of the total raised funds.

The company's net profit in 2024 was RMB 159.2089 million, and its weighted average return on net assets in 2024 was 10.94%, which meets the financial requirements for listing on the Beijing Stock Exchange.

The company plans to hold an extraordinary shareholders' meeting on December 16, 2025 to review relevant proposals. The announcement specifically notes that there is a risk that the listing application may not be approved.

Recently, Mr. Jiang, a man from Hangzhou, posted a video on social media, stating that he has filed a lawsuit with the Xuhui District People's Court of Shanghai, demanding that Align (Shanghai) Trading Co., Ltd. (the Chinese entity of Invisalign's parent company) disclose all his personal information related to his orthodontic and orthognathic treatment.

In the video, Mr. Jiang stated that he discovered that two institutions used unlicensed doctors during his orthodontic and orthognathic treatment, and subsequently requested relevant medical records from Invisalign.

In an email reply, Invisalign stated that the person responsible for Mr. Jiang's medical information was his attending physician, and suggested that he contact his attending physician or the medical institution to obtain the information. Mr. Jiang did not accept this response.

As of press time, Align (Shanghai) Trading Co., Ltd. has not issued a public statement on this matter, and there is no public information regarding whether the court has accepted the case.

Haili Biotechnology Co., Ltd. recently announced that it plans to acquire 41% of the equity of Shaanxi Ruisheng Biotechnology Co., Ltd. through an equity acquisition agreement, thereby increasing its shareholding from 55% to 96%.

The transaction was valued at RMB 399.3 million. Due to cash flow difficulties, Meilun Management Co., Ltd. proposed to use its 41% equity stake in Ruisheng Biotechnology to fulfill its obligation to refund the transaction price difference. Meilun is required to fulfill its performance commitment that Ruisheng Biotechnology's cumulative net profit from 2024 to 2026 will not be less than RMB 233 million.

The transaction has been approved by the board of directors of Haili Biological and is still subject to approval by the shareholders' meeting.

Shining 3D Technology Co., Ltd. recently released its review report for January-September 2025.

The report disclosed that the company achieved operating revenue of RMB 1.088 billion in the first nine months of 2025, a year-on-year increase of 36.29%; net profit attributable to the parent company of RMB 282 million, a year-on-year increase of 190.91%; and net cash flow from operating activities of RMB 290 million, a year-on-year increase of 194.59%.

In the third quarter, the company's operating revenue was RMB 400 million, a year-on-year increase of 45.36%; net profit attributable to the parent company was RMB 106 million, a year-on-year increase of 282.22%.

As of September 30, 2025, the company's total assets were RMB 2.327 billion, and its equity attributable to the parent company was RMB 1.857 billion. The company plans to issue shares publicly to raise funds for research and development projects in industrial 3D vision measurement and inspection, high-precision 3D vision algorithms, and digital dental implant technology. This matter is subject to shareholder approval.

The Fuqing Municipal Market Supervision Administration recently imposed an administrative penalty of 130,000 yuan on a dental hospital company in Longtian, Fuzhou, for using expired drugs and medical devices.

The inspection revealed that the hospital used a variety of expired medications and medical devices, including gentamicin solution, gentamicin sulfate injection, dexamethasone sodium phosphate injection, glass ionomer cement, occlusal paper, and denture base resin. The total value of the expired medications used by the hospital was 7.33 yuan, and the value of the expired medical devices was 219.26 yuan.

The penalty decision stated that the hospital did not charge extra for using expired drugs, which was its first offense, and it actively cooperated with the investigation; therefore, the penalty was relatively lenient. Ultimately, the hospital was fined 110,000 yuan for using substandard drugs and 20,000 yuan for using expired medical devices.

Recently, the Liaoning Provincial Health Commission issued a "Notice on Further Clarifying the Application Requirements for Attending Physicians in Clinical, Dental, and Traditional Chinese Medicine Categories," which clarifies that starting from November 2026, licensed physicians in the clinical, dental, and traditional Chinese medicine categories applying for the attending physician examination must provide a certificate of completion of standardized residency training.

The notice establishes a transitional management mechanism, allowing eligible personnel to register for the exam in advance between 2027 and 2029. For licensed physicians who entered medical and health institutions in 2020 or earlier and meet the requirements for applying for the attending physician exam, a standardized residency training certificate is not required.

This move aims to implement the requirements of the national professional title system reform and establish a professional title evaluation system that conforms to the characteristics of the health industry.

The Tianjin Municipal Health Commission recently released the "Implementation Measures for the Supervision of Internet-based Medical Services in Tianjin (Draft for Public Comment)," soliciting public opinions until December 9, 2025.

The measures clarify the regulatory framework for internet-based medical services in Tianjin. Medical institutions are required to establish dedicated departments to manage internet-based medical services and monitor medical quality and safety.

Internet-based medical services are subject to real-name registration, requiring patients to provide real identity verification. Physicians conducting internet-based medical services must possess the corresponding professional qualifications, and AI is prohibited from replacing physicians in consultations or automatically generating prescriptions.

The Shaanxi Provincial Health Commission recently released the "Shaanxi Provincial Measures for the Management of Scoring of Adverse Practice Behaviors of Medical Institutions (Draft for Public Comment)" and is soliciting public opinions.

This measure will establish a medical institution practice supervision mechanism based on a point-based system. According to the draft for comments, medical institutions that accumulate 12 points or more will face a temporary suspension of their verification process.

This measure involves scoring 150 types of unethical practices, covering areas such as practice licensing, personnel management, and medical documentation. During the grace period, practitioners accumulating 6 or more points will have their practice licenses revoked.

The Shaanxi provincial health administration department will establish a scoring information management platform to manage the adverse practices of medical institutions at all levels.

The Beijing Municipal Drug Administration recently released the "Beijing Municipal Measures for the Supervision and Management of Domestic Agents of Imported Medical Devices (Trial)," which will come into effect on January 1, 2026, with a trial period of 3 years.

The regulations clarify the conditions, obligations, and supervision and management of domestic agents for imported medical devices. Agents must have corresponding quality management organizations and professional personnel, and fulfill five obligations, including establishing a quality management system and monitoring adverse events.

The Beijing Municipal Drug Administration will be responsible for annual inspections and the establishment and updating of credit files for agents.

The Guizhou Provincial Medical Security Bureau, the Guizhou Provincial Health Commission, and the Guizhou Provincial Drug Administration recently jointly issued the "Implementation Rules for the Management of Medical Insurance Payment Qualifications of Relevant Personnel in Designated Medical Institutions in Guizhou Province".

The new detailed rules are revised from the trial version released in February 2025. A scoring management mechanism is established. If relevant personnel accumulate 9 or 10 points in a natural year, their medical insurance payment qualification will be suspended for 1 to 4 months respectively. If they accumulate 12 points, their qualification will be terminated, and they will not be allowed to register again within one year after termination.

The medical insurance agency is responsible for recording and processing scores, and relevant personnel can correct their scores through online learning and examinations. This measure aims to strengthen the management of medical insurance payment eligibility and ensure the quality of medical services.

Recently, the Hunan Provincial Medical Security Bureau and the Hunan Provincial Department of Finance jointly issued the "Implementation Rules for Rewarding Whistleblowers of Illegal and Irregular Use of Medical Security Funds in Hunan Province," which aims to encourage public participation in the supervision of medical insurance funds and safeguard their security.

The detailed rules establish a tiered reward system, with rewards based on 10%, 5%, or 3% of the amount reported, up to a maximum of 200,000 yuan.

Whistleblower information will be protected, and reward funds will be managed specifically by medical security administrative departments at all levels. These detailed rules will take effect from the date of promulgation and will be valid for five years.

The Inner Mongolia Autonomous Region Drug Administration recently released a draft of the "Guidelines for Medical Device Business Licensing (Filing) in Inner Mongolia Autonomous Region (Draft for Public Comment)" for public comment.

This guideline applies to the issuance and registration of medical device business licenses within the Inner Mongolia Autonomous Region, emphasizing requirements for personnel qualifications, quality management, and premises facilities.

The quality manager must possess a relevant professional degree and at least three years of experience. Companies must establish a comprehensive quality management system; business premises and warehouses must be located in the same building and are prohibited from being located in unsuitable locations. For companies dealing with refrigerated medical devices, appropriate refrigeration facilities are required, along with a temperature control emergency plan.

The Shanghai Municipal Drug Administration recently released a revised version of the "Shanghai Municipal Drug Administration's Measures for Holding Talks on Safety Responsibilities for Drugs, Medical Devices and Cosmetics," which will take effect immediately and remain in effect until December 1, 2030.

The Measures apply to the supervision of pharmaceuticals, medical devices, and cosmetics, and specify eight scenarios for interviews, including safety incidents, failure to eliminate safety hazards in a timely manner, and deficiencies in the quality management system.

The companies summoned for talks must send their legal representatives or relevant personnel to participate. The drug regulatory authorities will issue a notice of the talks and record the entire process. Companies that fail to rectify the issues as required will face increased frequency of inspections.

Recently, US dental AI company Overjet announced the acquisition of DentalBee, a voice-based clinical documentation platform. This acquisition expands its AI suite to include real-time clinical documentation and treatment guidance.

After the merger, Overjet's IRIS product and DentalBee's voice platform will enable a unified workflow for diagnostics, documentation, and revenue cycle management, supporting hands-free note-taking, automated clinical notes, and real-time visit capture.

This move aims to streamline the treatment process, reduce administrative burden, and improve case acceptance rates and patient communication efficiency. Overjet will continue to support DentalBee's existing customers and plans to open early access appointments for the voice AI feature.

Planmeca recently released its new dental 3D printer, the Planmeca Creo® X, which uses chip-packaged LED light source technology with 34-micron pixel resolution and a monochrome LCD panel to achieve precision printing.

This equipment can be used to manufacture custom instruments such as dental restorations, surgical guides, and dental models, and is equipped with an integrated heater for resin temperature control to optimize the printing effect of different materials.

Planmeca has redesigned the technology and core components based on its predecessor to ensure stable performance of the equipment in high-load environments.

Recently, the Israeli company NOVA Implant Systems sought to sell its "dual composite surface technology" to Chinese dental implant and orthopedic manufacturers.

This technology combines Novitex®microtextured surface with a highly crystalline hydroxyapatite (HA) coating, which can increase the effective surface area of ​​the implant and achieve a bone implant contact rate of over 98%.

Based on this, NOVA hopes to cooperate with Chinese manufacturers to introduce this technology to the Chinese market. Companies interested in cooperation can contact the Israeli Trade Office in China.

Scan the QR code to view more dental industry information.